"We see massive growth in the medical market. Across the board, from manufacturers to pharmacies, most players in the market have seen a growth of up to 100% or even more," says Philip Schetter, CEO of Cantourage, about the impact of Germany implementing the first part of Pillar 1 of its cannabis legalization on April 1st. Philip shares that Cantourage itself grew by 160% in April. "There's just a massive demand which is driven by there being more doctors and more patients. There are also now new business models popping up, which further ease the access for patients to get a prescription. It's a whole new world." In a recent webinar, hosted by Zuanic & Associates, three German companies discussed the changes they have noticed since last month.
